ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,487.03
0.25%
US Tech 100
19,430.40
0.14%
다우존스 지수
38,834.86
0.15%
Bitcoin
65,134.93
-0.01%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Poseida Therapeutics Inc (PSTX)

  7. Poseida Therapeutics Inc (PSTX) 뉴스

PSTX

Poseida Therapeutics (PSTX)

Poseida Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:PSTX
일자시간출처헤드라인심볼기업
2024/06/1905:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSTXPoseida Therapeutics Inc
2024/06/1905:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSTXPoseida Therapeutics Inc
2024/06/1905:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
2024/06/0405:05PR Newswire (US)Poseida Therapeutics Announces Virtual 2024 Annual Meeting of StockholdersNASDAQ:PSTXPoseida Therapeutics Inc
2024/05/1505:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PSTXPoseida Therapeutics Inc
2024/05/1505:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
2024/05/1505:05PR Newswire (US)Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024NASDAQ:PSTXPoseida Therapeutics Inc
2024/05/0922:00PR Newswire (US)Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual MeetingNASDAQ:PSTXPoseida Therapeutics Inc
2024/05/0613:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PSTXPoseida Therapeutics Inc
2024/05/0210:30PR Newswire (US)Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyNASDAQ:PSTXPoseida Therapeutics Inc
2024/05/0204:25AllPennyStocks.comBiotech Soars on Research Collaboration And License Agreement ReleaseNASDAQ:PSTXPoseida Therapeutics Inc
2024/05/0122:00PR Newswire (US)Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyNASDAQ:PSTXPoseida Therapeutics Inc
2024/04/1821:00PR Newswire (US)Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual MeetingNASDAQ:PSTXPoseida Therapeutics Inc
2024/04/1722:00PR Newswire (US)Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline FocusNASDAQ:PSTXPoseida Therapeutics Inc
2024/04/0901:00PR Newswire (US)Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple MyelomaNASDAQ:PSTXPoseida Therapeutics Inc
2024/04/0205:05PR Newswire (US)Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PSTXPoseida Therapeutics Inc
2024/03/2605:05PR Newswire (US)Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical OfficerNASDAQ:PSTXPoseida Therapeutics Inc
2024/03/2005:05PR Newswire (US)Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceNASDAQ:PSTXPoseida Therapeutics Inc
2024/03/1405:05PR Newswire (US)Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple MyelomaNASDAQ:PSTXPoseida Therapeutics Inc
2024/03/0806:07PR Newswire (US)Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023NASDAQ:PSTXPoseida Therapeutics Inc
2024/03/0806:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
2024/03/0507:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSTXPoseida Therapeutics Inc
2024/03/0507:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSTXPoseida Therapeutics Inc
2024/03/0506:05PR Newswire (US)Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PSTXPoseida Therapeutics Inc
2024/02/0906:10Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PSTXPoseida Therapeutics Inc
2024/01/0506:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSTXPoseida Therapeutics Inc
2024/01/0506:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
2024/01/0422:00PR Newswire (US)Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key MilestonesNASDAQ:PSTXPoseida Therapeutics Inc
2023/12/1200:31Dow Jones NewsPoseida Therapeutics Shares Climb on Positive Data for Blood Cancer TreatmentNASDAQ:PSTXPoseida Therapeutics Inc
2023/12/1120:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
 검색 관련기사 보기:NASDAQ:PSTX

최근 히스토리

COIN
ETHUSD
Ethereum
NASDAQ
AAPL
Apple
NYSE
DIS
Walt Disney
NYSE
NKE
Nike
USOTC
DTEGY
Deutsche Telekom (QX)
COIN
SOLUSD
Solana
NYSE
JPM
JP Morgan Chase
CCOM
SILVER
SILVER
PM
XAUUSD
Gold vs US Dollar
USOTC
BASFY
BASF (QX)
USOTC
RHHBY
Roche (QX)
AMEX
XLF
Financial Select Sector
SPI
SP500
S&P 500
AMEX
SPY
SPDR S&P 500
AMEX
XLE
Energy Select Sector SPDR
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유